Zydus Lifesciences Limited has announced that its Board of Directors will convene on May 19, 2026, to approve the audited financial results for the quarter and financial year ended March 31, 2026. The board will also consider a recommendation for a final dividend for the fiscal year. In preparation for the meeting, the company’s trading window will be temporarily closed for designated individuals until May 21, 2026.
Upcoming Board Meeting Details
The leadership team at Zydus Lifesciences is set to meet on Tuesday, May 19, 2026. The primary objective of this assembly is the formal review and approval of the company’s audited financial performance for the quarter and the full year concluding on March 31, 2026. This disclosure marks a significant milestone in the company’s annual financial reporting calendar.
Dividend Consideration
During the same meeting, the Board of Directors will evaluate the proposal for a final dividend payout for the financial year ended March 31, 2026. Any dividends approved will be communicated to shareholders following the conclusion of the board meeting and the subsequent release of the audited financial statements.
Trading Window Regulations
To maintain market integrity during this period, the company has implemented a temporary closure of its trading window for all Directors and designated employees. This window will remain closed until Thursday, May 21, 2026. Normal trading operations for these individuals are scheduled to resume on Friday, May 22, 2026.
Source: BSE
